Skip to main content
CMEducation Resources ScrollCall
  • menu
  • menu
  • person
  • Search
  • Specialty
  • Cardiology chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • Diabetes chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • Specialty Program
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Cytokine Immunotherapy chevron_right
  • Hypothyroidism chevron_right
  • Specialty Program
  • Parkinson's Diseasechevron_right
  • Specialty
  • Cancer chevron_right

  • Specialty Program
  • Cytokine Immunotherapy chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Pain Management chevron_right
  • Specialty
  • Primary Care chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Parkinson's Diseasechevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • Specialty
  • Dermatology chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Specialty
  • Biologicschevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Biosimilars for RA chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • MAC Lung Disease chevron_right

  • Specialty Program
  • MAC Lung Disease chevron_right
    • close
    CMEducation Resources iQ&A
    • person
    • Home
    • Specialtieschevron_right
      • chevron_leftTopics
      • Cardiology
      • Diabetes
      • Endocrinology
      • Neurology
      • Cancer
      • Primary Care
      • Dermatology
      • Biologics
      • MAC Lung Disease
    • Submit A Question
    close

    Paul Ridker, MD

    Paul Ridker, MD

    Eugene Braunwald Professor

    Harvard Medical School

    Division of Cardiovascular Medicine

    Director, Center for Cardiovascular Disease Prevention

    Brigham and Women’s Hospital

    Boston, MA


    Related Videos

    You have identified the challenges of accessing PCSK9 inhibitors for patients whose CV risk is genetic vs. those whose clinical course is characterized by progressive vascular events. How do you approach each subset with respect to LDL-C management? Video

    You have identified the challenges of accessing PCSK9 inhibitors for patients whose CV risk is genetic vs. those whose clinical course is characterized by progressive vascular events. How do you approach each subset with respect to LDL-C management?

    As a leading authority in LDL-C-mediated CV risk reduction, can you provide us with your perspective on the evidence for PCSK9 inhibitors as a foundational approach for managing a broad spectrum of patients with high risk coronary heart disease? Video

    As a leading authority in LDL-C-mediated CV risk reduction, can you provide us with your perspective on the evidence for PCSK9 inhibitors as a foundational approach for managing a broad spectrum of patients with high risk coronary heart disease?

    Based on ODYSSEY Outcomes, for which biological/metabolic risk markers do you feel that cardiologists and atherosclerosis specialists should strive to achieve LDL-C levels even more aggressive than those identified in the AHA Guidelines? Video

    Based on ODYSSEY Outcomes, for which biological/metabolic risk markers do you feel that cardiologists and atherosclerosis specialists should strive to achieve LDL-C levels even more aggressive than those identified in the AHA Guidelines?

    How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy? Video

    How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?

    How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy? Video

    How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?

    From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction? Video

    From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction?

    IC and lipid specialists are challenged to maximize CV risk reduction in high-risk populations. How should they approach the 70 mg/dL LDL-C target identified in the AHA Guidelines, and when is the 30 mg/dL – 70 mg/dL even more desirable? Video

    IC and lipid specialists are challenged to maximize CV risk reduction in high-risk populations. How should they approach the 70 mg/dL LDL-C target identified in the AHA Guidelines, and when is the 30 mg/dL – 70 mg/dL even more desirable?

    Professor Bhatt, you presented the pharmacoeconomic “in trial” analysis for alirocumab based on the ODYSSEY Outcomes Trial. Can you discuss the clinical implications of your analysis, and how reduced costs for alirocumab will affect IC practice? Video

    Professor Bhatt, you presented the pharmacoeconomic “in trial” analysis for alirocumab based on the ODYSSEY Outcomes Trial. Can you discuss the clinical implications of your analysis, and how reduced costs for alirocumab will affect IC practice?

    What other markers, besides LDL-C levels, do you believe we should consider to refine CV risk stratification? Video

    What other markers, besides LDL-C levels, do you believe we should consider to refine CV risk stratification?

    Disclaimer:
    Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
    Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
    Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
    Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

    Clinical Webcasts®

    Powered by BroadcastMedBROADCASTMED